CCIA
MRTX

Campbell & Co Investment Adviser’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-31,587
Closed -$1.38M – 1410
2023
Q3 		$1.38M Buy
+31,587
New +$1.13M 0.16% 174
2022
Q3 		– Sell
-6,557
Closed -$440K – 989
2022
Q2 		$440K Buy
6,557
+2,634
+67% +$168K 0.12% 318
2022
Q1 		$323K Buy
+3,923
New +$401K 0.09% 450

Other funds holding MRTX

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Campbell & Co Investment Adviser's MRTX Position: Q4 2023 in Review

Campbell & Co Investment Adviser sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 31,587 shares — an estimated $1.38M sold.

Campbell & Co Investment Adviser first reported a position in MRTX in Q1 2022 and held it in 3 quarters. The position peaked at $1.38M in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Campbell & Co Investment Adviser reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 31,587 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $1.38M.
  • Campbell & Co Investment Adviser first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Mirati Therapeutics, Inc. Common Stock position peaked at $1.38M in Q3 2023.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2023, filed 13 Feb 2024.